See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $242B | 3.7x | 8.5x | |
| $194B | 3.1x | 7.9x | |
| $132B | 2.5x | 8.5x | |
| $98.8B | 2.3x | 6.8x | |
| $80.8B | 5.1x | 15.3x | |
| $44.2B | 5.7x | 20.1x | |
| $10.6B | 4.0x | -7.4x | |
| $9.6B | n/a | n/a | |
| $9.4B | 3.9x | 42.2x | |
| $6.8B | 7.3x | 26.0x | |
| $5.8B | 2.4x | -1.5x | |
| $5.1B | 11.5x | 36.5x | |
| $4.6B | 13.1x | 92.0x | |
| $4.0B | 5.9x | 15.1x | |
| $3.1B | 7.7x | 31.9x | |
| $2.9B | 17.1x | -48.2x | |
| $2.7B | 2.9x | 8.4x | |
| $2.6B | n/a | n/a | |
| $2.5B | 6.4x | 26.5x | |
| $2.5B | 32.9x | n/a | |
| $2.3B | n/a | n/a | |
| $2.2B | 6.3x | -93.1x | |
| $1.7B | 45.5x | -64.7x | |
| $1.5B | 7.3x | 19.6x | |
| $1.5B | n/a | n/a | |
| $1.4B | 8.3x | 27.8x | |
| $1.3B | 8.3x | 9.1x | |
| $1.3B | 7.2x | 30.4x | |
| $1.2B | 2629.3x | n/a | |
| $1.2B | n/a | n/a | |
| $1.1B | 9.2x | 111.4x | |
| $1.0B | 4.8x | -67.4x | |
| $1.0B | 5.7x | n/a | |
| $971M | 6.4x | 13.1x | |
| $956M | 3.0x | 42.7x | |
| $926M | 4.0x | 12.8x | |
| $855M | 0.9x | 4.3x | |
| $835M | 171.3x | -3.7x | |
| $802M | 3.0x | 64.3x | |
| $608M | n/a | n/a | |
| $606M | n/a | n/a | |
| $602M | 75.8x | -2.5x | |
| $588M | 7.5x | -23.4x | |
| $579M | 551.6x | -29.8x | |
| $564M | 219.7x | -4.3x | |
| $540M | n/a | -8.6x | |
| $460M | 2.0x | n/a | |
| $453M | 7.3x | -3.6x | |
| $433M | n/a | n/a | |
| $383M | 18.9x | -1272.2x | |
| $349M | 404916.4x | -14.3x | |
| $346M | 2.0x | 8.5x | |
| $321M | 86.8x | n/a | |
| $321M | 645.8x | n/a | |
| $319M | 3.1x | -3.5x | |
| $313M | 1.3x | -0.9x | |
| $296M | 946.0x | n/a | |
| $279M | n/a | n/a | |
| $268M | 1.4x | 6.5x | |
| $227M | 1.6x | n/a | |
| $225M | n/a | -6.3x | |
| $220M | n/a | n/a | |
| $194M | n/a | n/a | |
| $190M | n/a | n/a | |
| $189M | 17.4x | n/a | |
| $184M | 1.7x | 8.0x | |
| $180M | n/a | n/a | |
| $172M | n/a | n/a | |
| $158M | n/a | n/a | |
| $157M | 2.3x | 7.2x | |
| $155M | n/a | n/a | |
| $150M | 27.0x | -9.6x | |
| $148M | 1.6x | -1.1x | |
| $144M | n/a | n/a | |
| $138M | 9.1x | n/a | |
| $138M | n/a | n/a | |
| $138M | 5.3x | -8.1x | |
| $132M | n/a | n/a | |
| $130M | n/a | n/a | |
| $110M | 53.2x | -0.3x | |
| $105M | 3.0x | -0.2x | |
| $104M | 36108.1x | -4.1x | |
| $96.8M | n/a | -1.1x | |
| $94.5M | n/a | n/a | |
| $90.7M | n/a | -3.1x | |
| $88.2M | 1.0x | 1004.3x | |
| $80.5M | 20.3x | n/a | |
| $79.6M | n/a | n/a | |
| $76.0M | 0.6x | 36.5x | |
| $76.0M | 1.5x | -0.4x | |
| $71.4M | n/a | n/a | |
| $64.6M | 479.4x | n/a | |
| $60.0M | 4.3x | n/a | |
| $55.1M | n/a | -2.4x | |
| $54.6M | 5444.9x | -0.2x | |
| $53.2M | 847.3x | n/a | |
| $51.4M | 17.6x | -1.7x | |
| $46.5M | n/a | n/a | |
| $43.4M | 2.4x | n/a | |
| $42.5M | 4.9x | n/a | |
| $40.3M | n/a | n/a | |
| $40.3M | n/a | -1.0x | |
| $39.2M | n/a | n/a | |
| $38.1M | 0.4x | -0.7x | |
| $31.5M | 0.7x | -0.3x | |
| $29.6M | 797.0x | n/a | |
| $23.7M | n/a | n/a | |
| $19.8M | 32.8x | n/a | |
| $17.6M | 6.9x | n/a | |
| $17.0M | 24.7x | n/a | |
| $16.0M | 7.1x | -1.1x | |
| $12.7M | n/a | n/a | |
| $11.5M | 2.1x | n/a | |
| $10.8M | n/a | n/a | |
| $9.3M | 1.3x | n/a | |
| $4.5M | n/a | n/a | |
| $3.2M | 0.8x | -0.2x | |
| -$1.2M | -0.2x | n/a | |
| -$4.6M | -2.3x | 0.1x | |
| -$6.7M | n/a | n/a | |
| -$13.5M | -1.5x | 0.1x | |
| -$14.1M | n/a | 0.2x | |
| -$17.0M | n/a | n/a | |
| -$22.6M | -3.1x | 0.2x | |
| -$23.4M | n/a | 0.1x | |
| -$25.6M | -858.8x | 0.1x | |
| -$26.0M | -4.8x | n/a | |
| -$32.5M | n/a | n/a | |
| -$36.1M | n/a | 0.3x | |
| -$46.4M | n/a | n/a | |
| -$47.3M | -13.5x | 1.2x | |
| -$48.2M | -0.4x | n/a | |
| -$50.9M | n/a | 0.3x | |
| -$52.8M | n/a | n/a | |
| -$59.4M | -8.0x | 0.4x | |
| -$61.7M | -684.4x | n/a | |
| -$64.9M | n/a | n/a | |
| -$65.3M | -0.5x | 0.6x | |
| -$79.3M | -2.9x | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies